---
title: CDMO Daily News — August 1, 2026
slug: daily-news-2026-08-01-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: August 1 CDMO daily: AdvanCell Breaks Ground on Andover, MA Manufacturing Facility for Targeted Alpha Therapies; Resilience and Eli Lilly Expand Ohio…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-08-01-cdmo
published_at: 2026-08-01T00:00:06.465Z
last_updated: 2026-08-01T00:03:23.695Z
---

### AdvanCell Breaks Ground on Andover, MA Manufacturing Facility for Targeted Alpha Therapies
- AdvanCell held a groundbreaking ceremony for a 128,000-square-foot U.S. headquarters and manufacturing facility in Andover, Massachusetts.
- The facility represents AdvanCell's first internal U.S. manufacturing site and will support production scaling for clinical and commercial targeted alpha therapy programs.

**Operational Impact**

AdvanCell's new Andover facility adds U.S.-based manufacturing capacity for targeted alpha therapies, reducing reliance on contract manufacturing for clinical and commercial supply of its pipeline programs.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/advancell-breaks-ground-on-new-u-s-headquarters-flagship-manufacturing-facility)*

---

### [Resilience](/companies/resilience) and Eli Lilly Expand Ohio Manufacturing Partnership With $750M Investment
- [Resilience](/companies/resilience) and Eli Lilly are investing $750 million combined to add KwikPen injectable-device production at Resilience's Ohio facilities, with operations launching in early 2027.
- The expansion will create at least 400 new jobs and grow Resilience's Ohio workforce to over 1,400 across two Cincinnati-region sites totaling nearly 1 million square feet.
- The multi-year partnership, begun in 2023, has already produced more than 150 million doses in vial and pre-filled syringe formats for U.S. diabetes and obesity medicines.

**Operational Impact**

[Resilience](/companies/resilience)'s Ohio expansion adds domestic fill-finish and device-assembly capacity for high-volume diabetes and obesity injectables, reducing reliance on offshore CDMO partners for Lilly's critical commercial programs.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/resilience-and-lilly-expand-us750-million-partnership-to-increase-ohio-manufacturing)*

## References

1. [Contract Pharma Breaking News RSS — AdvanCell Breaks Ground on Andover, MA Manufacturing Facility for Targeted Alpha The](https://www.contractpharma.com/breaking-news/advancell-breaks-ground-on-new-u-s-headquarters-flagship-manufacturing-facility)
2. [PharmaSource RSS — Resilience and Eli Lilly Expand Ohio Manufacturing Partnership With $750M Investment](https://pharmasource.global/content/news/cdmo-news/resilience-and-lilly-expand-us750-million-partnership-to-increase-ohio-manufacturing)

Source: https://www.cdmo.directory/posts/daily-news-2026-08-01-cdmo